Testosterone treatment in older men: glass half empty or half full?

Brendan J Nolan¹, Mathis Grossmann²

Asian Journal of Andrology (2017) 19, 512–514; doi: 10.4103/aja.aja_14_17; published online: 26 May 2017

In a series of randomized controlled trials published in JAMA and JAMA Intern Med, US researchers have examined the effect of testosterone treatment in older men with testosterone levels <275 ng dl⁻¹ on coronary artery plaque volume,¹ cognitive function,² anemia,³ and volumetric bone density.⁴ While the trials have shown positive results with respect to improvement in anemia and bone density, longer-term studies are required to delineate the long-term risks and benefits in this population.

Testosterone levels in men decrease with age. However, previous trials examining the effect of testosterone treatment have produced equivocal results. A panel at the Institute of Medicine of the National Academy of Science, therefore, recommended a set of clinical trials to determine the benefits of testosterone replacement on symptoms and age-associated conditions in this population. The Testosterone (T) Trials were a coordinated series of seven double-blind, placebo-controlled trials (RCT) conducted at 12 academic centers in North America designed to answer this question.⁵

Eligible men were ≥65 years with a total serum testosterone concentration that averaged <275 ng dl⁻¹ on two measurements, and at least one of decreased libido, difficult walking or low vitality. Key exclusion criteria include pathological hypogonadism, and high cardiovascular or prostate risk.⁶ Remarkably, it was necessary to screen 51 085 men to enroll 790 participants meeting all criteria. Only 14.7% of the men with blood samples had a sufficiently low testosterone level to qualify for the study. Sixty-three percent of the participants were obese, 72% had hypertension, 37% diabetes, and 15% a previous myocardial infarction.³ Men were randomly assigned to receive testosterone gel, adjusted to maintain the serum testosterone level within the reference range for young men, or placebo gel for 12 months. Initial results of the Sexual Function Trial, Physical Function Trial and Vitality Trial were published in the N Engl J Med in 2016 (Table 1).⁶

In the February 2017 issue of the JAMA, Budoff et al.⁷ reported the findings of the Cardiovascular Trial. This trial assessed the effects of testosterone treatment on non calcified coronary artery plaque volume by coronary computed tomographic angiography measured in a subset of 138 men at baseline and at the end of the 12-month RCT. In these men with relatively high coexisting comorbidities, testosterone treatment was associated with a significantly greater increase in noncalcified plaque volume from baseline to 12 months, rather than reducing this potential early marker of cardiovascular risk.¹

Moreover, they found that the predictive value of coronary artery plaque volume for future cardiovascular events is unclear, and a 3-year RCT in a different population of older US American men with lowered testosterone levels showed no effect of testosterone treatment on carotid artery intimal media thickness.⁷

In the same issue of the JAMA, Resnick et al.² reported the results of the Cognitive Function Trial, which examined the effect of testosterone replacement on verbal memory and other cognitive functions in 493 men with low serum testosterone and evidence of age-associated memory impairment at baseline. After 12 months, testosterone produced no benefit in the primary outcome measure of the delayed paragraph recall score, or in the secondary outcomes of visual memory, executive function, or spatial memory.

The results of the remaining two trials were published in the JAMA Intern Med. The Anemia Study analyzed the effect of testosterone replacement in 126 men with anemia, of which 62 had unexplained anemia. Testosterone treatment increased the hemoglobin levels in men both with unexplained anemia or anemia from known cause.⁷ In explanatory analyses, changes in hemoglobin levels were associated with increases in vitality and walking distance, but effects were small and below cut-offs considered clinically meaningful. However, the authors reported that greater increases in hemoglobin levels were associated with the trial participants global impression in overall health and energy, pointing to the possibility that the increase in hemoglobin levels (overall 0.83 g dl⁻¹ [95% CI: 0.48–1.39]) might be of clinical significance. Moreover, the findings indicate that androgen deficiency should be excluded in men with unexplained anemia by measurement of their testosterone levels.

Finally, the Bone Study reported the results of 207 participants and demonstrated that testosterone treatment significantly increases volumetric bone mineral density (BMD) and estimated bone strength, more in trabecular bone than peripheral bone and more in the spine than the hip.⁴ Baseline mean BMD by DEXA was normal in these men. Long-term studies are required to establish if this equates to a reduction in fracture risk.

To date, the T trials provide the best evidence available on the short-term effects of testosterone treatment in older men without pathological hypogonadism. These high-quality trials were rigorously designed and conducted, and randomized carefully.
selected older men with both clinical as well as biochemical evidence of androgen deficiency. However, the T trials were not designed to evaluate long-term risks. Overall, the results were mixed: on the one hand, testosterone treatment provided modest improvements in sexual function and some aspects of mood, and increases in bone density and bone strength, and in hemoglobin levels. On the other hand, testosterone treatment had no benefits on cognitive function, on overall vitality or physical activity, and of potential concern, increased coronary artery plaque. The clinical implications of these findings are not yet clear, and larger studies are needed to determine clinically important benefits and potential long-term risks of testosterone treatment, such as on cardiovascular and prostate health, fracture rates, and functional independence.

The low enrollment to screening ratio in the T trials is consistent with findings from the European Male Aging Study (EMAS), which reported a 2.1% prevalence of late-onset hypogonadism, lower than previous studies using less stringent criteria. Moreover, in both studies,6,8 men had relatively high rates

---

**Table 1: Testosterone trials: key outcomes**

| Trial                        | Key inclusion and exclusion criteria                                                                 | Number of subjects | Primary outcome                  | Results                                      |
|------------------------------|-------------------------------------------------------------------------------------------------------|--------------------|----------------------------------|---------------------------------------------|
| Sexual function trial²       | Inclusion criteria: Self-reported decreased libido, a score of 20 or less on the sexual-desire domain of the DISF-M-II, and partner willing to have intercourse twice a month | 459                | PDQ-Q4 score                     | Between-group differences                   |
|                              |                                                                                                      |                    |                                  | Primary outcome                             |
|                              |                                                                                                      |                    | ↑ PDQ-Q4 score, P<0.001          | Secondary outcomes                          |
|                              |                                                                                                      |                    | ↑ DISF-M-II sexual desire score, P<0.001 |                              |
|                              |                                                                                                      |                    | ↑ IIEF erectile function score, P<0.001 |                              |
| Physical function trial²     | Inclusion criteria: Self-reported walking difficulty or climbing stairs and a gait speed of <1.2 m s⁻¹ on the 6-min walk test | 387                | Increase of ≥50 m in 6-min walk test | Between-group differences                   |
|                              | Exclusion criteria: Men who were not ambulatory or who had disabling neuromuscular or arthritic conditions |                    |                                  | Primary outcome                             |
|                              |                                                                                                      |                    | Increased of ≥50 m in 6-min walk test, P=NS |                              |
|                              |                                                                                                      |                    | 6-min walking distance, P=NS      |                              |
|                              |                                                                                                      |                    | Increase of ≥8 in PF-10 score, P=NS |                              |
|                              |                                                                                                      |                    | ↑ PF-10 score, P=0.03            |                              |
| Vitality trial²              | Inclusion criteria: Self-reported low vitality and a score of <40 on the FACIT-Fatigue scale          | 474                | Increase of ≥4 in FACIT-Fatigue score | Between-group differences                   |
|                              |                                                                                                      |                    |                                  | Primary outcome                             |
|                              |                                                                                                      |                    | ↑ FACIT-Fatigue score, P=0.30    | Secondary outcomes                          |
|                              |                                                                                                      |                    | ↑ FACIT-Fatigue score, P=NS      |                              |
|                              |                                                                                                      |                    | ↑ SF-36 vitality score, P=0.03   |                              |
|                              |                                                                                                      |                    | ↑ PANAS positive affect score, P=0.04 |                              |
|                              |                                                                                                      |                    | ↑ PANAS negative affect score, P<0.001 |                              |
|                              |                                                                                                      |                    | ↑ PHQ-9 depression score, P=0.004 |                              |
| Cardiovascular trial³        | Exclusion criteria: Myocardial infarction or stroke within 3 months, systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg | 138                | Noncalcified coronary artery plaque volume by coronary computed tomographic angiography | Between-group differences                   |
|                              |                                                                                                      |                    |                                  | Primary outcome                             |
|                              |                                                                                                      |                    | ↑ Noncalcified coronary plaque volume, P=0.003 |                              |
|                              |                                                                                                      |                    | Secondary outcomes                          |
|                              |                                                                                                      |                    | ↑ Total coronary plaque volume, P=0.006 |                              |
|                              |                                                                                                      |                    | Coronary artery calcium score, P=NS |                              |
| Cognitive function trial³    | Inclusion criteria: AAMI subjective memory complaints and relative impairment on objective tests of memory performance | 493                | Delayed paragraph recall score    | Between-group differences                   |
|                              | Exclusion criteria: Cognitive impairment, severe depression                                           |                    |                                  | Primary outcome                             |
|                              |                                                                                                      |                    | Delayed paragraph recall score, P=NS |                              |
|                              |                                                                                                      |                    | Secondary outcomes                          |
|                              |                                                                                                      |                    | Visual memory, P=NS                |                              |
|                              |                                                                                                      |                    | Spatial ability, P=NS              |                              |
|                              |                                                                                                      |                    | Executive function, P=NS          |                              |
| Anemia trial³                | Inclusion criteria: Baseline hemoglobin 12.7 g dl⁻¹ or lower                                          | 783                | Hemoglobin (≥1 g dl⁻¹ from baseline) in men with unexplained anemia | Between-group differences                   |
|                              | Exclusion criteria: Hemoglobin <10.0 g dl⁻¹                                                         |                    |                                  | Primary outcome                             |
|                              |                                                                                                      |                    | ↑ Hemoglobin ≥1 g dl⁻¹, P=0.002   |                              |
|                              |                                                                                                      |                    | Secondary outcome                 |
|                              |                                                                                                      |                    | ↑ Hemoglobin, P=0.001             |                              |
| Bone trial⁴                  | Exclusion criteria: Taking a medication known to affect bone, did not have at least one evaluable lumbar vertebra, DEXA T-score <−3.0 at any site | 207                | Spine trabecular bone volumetric BMD by QCT | Between-group differences                   |
|                              |                                                                                                      |                    |                                  | Primary outcome                             |
|                              |                                                                                                      |                    | ↑ Volumetric BMD of spine trabecular bone, P=0.001 |                              |
|                              |                                                                                                      |                    | Secondary outcomes                          |
|                              |                                                                                                      |                    | ↑ Volumetric BMD of spine peripheral bone, spine whole bone, hip trabecular bone, hip peripheral bone, hip whole bone, P=0.001 |                              |
|                              |                                                                                                      |                    | ↑ Bone strength by finite element analysis of spine whole bone, spine trabecular bone, spine peripheral bone, hip whole bone, hip peripheral bone, P=0.0001 |                              |
|                              |                                                                                                      |                    | ↑ Lumbar spine areal BMD, P<0.01 |                              |
|                              |                                                                                                      |                    | Total hip areal BMD, P=NS         |                              |
|                              |                                                                                                      |                    | Femoral neck areal BMD, P=NS      |                              |

NS: not significant; FACIT: Functional Assessment of Chronic Illness Therapy; PDQ: Psychosexual Daily Questionnaire; BMD: bone mineral density; QCT: quantitative computed tomography; PANAS: Positive and Negative Affect Schedule; DISF-M-II: Derogatis Interview for Sexual Functioning in Men–II; IIEF: International Index of Erectile Function; DEXA: dual-energy X-ray absorptiometry; PF-10: Physical Functioning-10; SF-36: Short Form-36; AAMI: age-associated memory impairment.

---
of comorbidities, including obesity and diabetes. Whether coexisting comorbidities contribute to androgen deficiency like symptoms and lowered testosterone levels is unknown. However, there is modest evidence suggesting that optimizing comorbidities, and especially weight loss can, in addition to general health benefits, increase testosterone levels, and improve androgen deficiency like symptoms in older men. Therefore, lifestyle measures and meticulous care of comorbidities should be the cornerstone focus within the context of a holistic approach to age-related hypogonadism, irrespective of whether testosterone treatment is considered or not.

**COMPETING INTERESTS**

Both authors declare no competing interests.

**REFERENCES**

1. Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, Wenger NK, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. *JAMA* 2017; 317: 708–16.
2. Resnick SM, Matsumoto AM, Stephens-Shields AJ, Ellenberg SS, Gill TM, et al. Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment. *JAMA* 2017; 317: 717–27.
3. Roy CN, Snyder PJ, Stephens-Shields AJ, Artz AS, Bhasin S, et al. Association of testosterone levels with anemia in older men: a controlled clinical trial. *JAMA Intern Med* 2017; 177: 480–90.
4. Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. *JAMA Intern Med* 2017; 177: 471–9.
5. Snyder PJ, Ellenberg SS, Cunningham GR, Matsumoto AM, Bhasin S, et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. *Clin Trials (London, England)* 2014; 11: 362–75.
6. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, et al. Effects of testosterone treatment in older men. *N Engl J Med* 2016; 374: 611–24.
7. Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. *JAMA* 2015; 314: 570–81.
8. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med* 2010; 363: 123–35.
9. Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. *J Clin Endocrinol Metab* 2017; 102: 1067–75.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

© The Author(s) (2017)
Author/s:
Nolan, BJ; Grossmann, M

Title:
Testosterone treatment in older men: glass half empty or half full?

Date:
2017-09-01

Citation:
Nolan, BJ; Grossmann, M, Testosterone treatment in older men: glass half empty or half full?, ASIAN JOURNAL OF ANDROLOGY, 2017, 19 (5), pp. 512 - 514

Persistent Link:
http://hdl.handle.net/11343/227570

File Description:
Published version